For over two thousand years, Chinese medicine has prescribed astragalus root as a tonic for vitality. In the last decade it acquired a more specific — and more seductive — reputation: as one of the few natural compounds claimed to actually lengthen your telomeres, the protective caps on your DNA that shorten as you age. That claim has real data behind it. Whether it matters for how you actually feel and function is a separate question — and the answer is more uncomfortable than the marketing suggests. We read the studies so you don’t have to.
Evidence Tier: 🥈 Silver — a meta-analysis of 8 human trials shows genuine telomere lengthening, and network meta-analyses support real heart-failure benefits, but the headline longevity claim has not translated into functional or lifespan improvements in people.
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Strongest benefit: A 2025 meta-analysis of 8 randomized trials (750 people) found the astragalus extract TA-65 lengthened telomeres, with a bigger effect in people over 60.
- Heart health: Network meta-analyses of trials find astragalus-containing formulas improve heart-failure measures like six-minute walk distance, BNP, and ejection fraction.
- Joint support: A 2026 12-week randomized trial found astragalus saponins improved knee function, mobility, and quality-of-life scores.
- Safety record: In the TA-65 trials side effects were mild (mostly stomach upset), with no severe adverse events over 12 months.
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- Biggest limitation: Telomere lengthening did not translate into better strength, frailty scores, or lower inflammation — a “telomere-function disconnect.”
- Industry bias: Trials funded by the TA-65 maker reported larger effects than independent trials (effect size 0.63 vs 0.40).
- Drug interactions: The compound cycloastragenol inhibits liver enzymes (CYP3A4, CYP2E1, CYP2C19), so it can change how other medications are metabolized.
- Cancer caution: Activating telomerase could in theory help existing cancers grow; long-term cancer risk has never been studied.
What Is Astragalus?
Astragalus (Astragalus membranaceus) is a plant in the pea family whose root — known as huáng qí in Chinese medicine — has been used as a general tonic for more than two millennia. Traditional texts describe it as “tonifying qi and strengthening the spleen,” which is another way of saying it was given to people who were run down, aging, or recovering from illness.
What makes astragalus interesting to longevity researchers is a cluster of molecules inside the root. The three that matter most are astragaloside IV (AS-IV), cycloastragenol (CAG), and the astragalus polysaccharides (APS). Cycloastragenol — and its commercial, lab-refined cousin TA-65 — is the one behind the telomere headlines: in cells, it appears to switch on telomerase, the enzyme that rebuilds telomeres.
How It Works
Astragalus is unusual because it appears to act through several pathways at once, depending on which compound you look at:
- Telomerase activation — cycloastragenol and TA-65 are reported to turn on telomerase, the enzyme that extends telomeres, the protective caps on the ends of your chromosomes that shorten each time a cell divides.
- Antioxidant defense — astragaloside IV and the polysaccharides activate the Nrf2 pathway, your cells’ built-in antioxidant switch, helping clear damaging reactive molecules.
- Calming inflammation — astragaloside IV and cycloastragenol dampen NF-κB and the NLRP3 inflammasome, two of the main switches behind chronic, age-related inflammation.
- Immune modulation — the polysaccharides appear to nudge the immune system, partly by feeding beneficial gut bacteria that produce short-chain fatty acids.
- Mitochondrial cleanup — in animal models, astragaloside IV boosts mitophagy (the recycling of damaged mitochondria) via the PINK1/Parkin pathway.
Most of this mechanistic detail comes from cell and animal studies, which is worth holding in mind as you read on.
The Longevity Connection
Here is where astragalus stands, outcome by outcome, ordered by how strong the human evidence is.
🥈 Telomeres — real lengthening, unclear payoff
The headline finding comes from a 2025 systematic review and meta-analysis published in Cell Biology and Toxicology. It pooled 8 randomized controlled trials (750 participants, average age 63) testing TA-65. The result: a moderate increase in telomere length (standardized mean difference 0.47), and the effect was larger in people over 60 (0.63) than in younger adults (0.36). So the telomere claim is not fabricated — the effect is real and measurable.
But the same analysis found something the marketing rarely mentions: the telomere growth did not translate into better function. Frailty scores barely moved (effect 0.09, not significant), and inflammatory markers like CRP and IL-6 did not improve either. The authors called this a “telomere-function disconnect” — longer telomeres on paper, with no measurable change in how old the person’s body actually behaved.
🥈 Heart failure — the best-supported clinical use
Where astragalus has the most consistent human data is as an add-on for heart failure, mostly in Chinese clinical research. A 2026 network meta-analysis of 18 trials (1,584 patients) found astragalus-containing formulas added to standard care improved outcomes — walk distance, BNP (a heart-stress hormone), and ejection fraction — beyond standard care alone. A separate 2026 randomized trial (200 patients) using astragalus injection reported similar improvements in BNP, ejection fraction, and six-minute walk distance. A third network meta-analysis found astragalus extract ranked best among 15 plant extracts for improving the six-minute walk test.
🥈 Joints — encouraging but preliminary
A 2026 randomized, double-blind, placebo-controlled trial in Nutrients gave healthy adults with knee discomfort astragalus saponins for 12 weeks. People in the astragalus group improved their step count and knee mobility and reported better quality-of-life scores — but the between-group differences against placebo did not reach statistical significance, which means we can’t yet rule out a placebo effect. In animal and cell models, cycloastragenol and astragaloside IV also reduced cartilage breakdown and cellular senescence in osteoarthritis.
🥉 Brain — early and mixed
A 2026 meta-analysis of three randomized trials in Alzheimer’s disease found astragalus improved one dementia rating scale (CDR-SB) but not memory or cognition scores. That’s a weak, mixed signal. A large body of preclinical work suggests astragaloside IV and cycloastragenol are neuroprotective, but human data is thin.
⚠️ Metabolic, immune, skin — mostly preclinical
Astragaloside IV shows anti-diabetic and liver-protective effects in animal models, and astragalus polysaccharides modulate the gut microbiome in cell and animal studies — but these have not been confirmed in large human trials. A systematic review found astragalus extracts used in skincare improved hydration and wrinkles in small trials, but the cosmetic evidence is early.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| Cell Biol Toxicol, 2025 | Meta-analysis of 8 RCTs (n=750, mean age 63) | TA-65 lengthened telomeres (SMD 0.47) but did not improve frailty or inflammation; industry-funded trials showed larger effects. |
| Medicine, 2026 | Network meta-analysis, 18 RCTs (n=1,584) | Astragalus-containing formulas plus standard care improved heart-failure outcomes vs standard care alone. |
| Front Med, 2026 | Randomized double-blind RCT (n=200) | Astragalus injection improved BNP, ejection fraction, and six-minute walk distance in heart failure. |
| Nutrients, 2026 | 12-week RCT, astragalus saponins vs placebo | Within-group knee and mobility gains; between-group differences not statistically significant. |
| Neuroscience, 2026 | Meta-analysis of 3 RCTs (Alzheimer’s) | Improved CDR-SB dementia rating but not MMSE or memory scores. |
| Arch Biochem Biophys, 2026 | In vitro, human liver microsomes | Cycloastragenol inhibits CYP3A4, CYP2E1, and CYP2C19 — a drug-interaction risk. |
| Sci Rep / Eur J Pharmacol, 2026 | Animal + cell models (OA, atherosclerosis) | Cycloastragenol restored cartilage; astragaloside IV reduced arterial plaque via Nrf2/mitophagy. |
Dosing and Safety
What the Trials Used
| Use Case | Typical Dose | Notes |
|---|---|---|
| Telomerase / “anti-aging” (TA-65) | 10–50 mg/day | The dose range used across the 8 clinical trials in the meta-analysis. |
| Whole-root extract (traditional use) | 500 mg–3 g/day | Often standardized to astragalosides or polysaccharides; evidence is mostly traditional/observational. |
| Joint support (astragalus saponins) | One capsule daily (12 weeks) | Specific AMS extract used in the 2026 knee trial; brand-dependent. |
| Heart-failure adjunct (injection) | Practitioner-administered | Astragalus injection is a clinical treatment in China, not a supplement. |
Side Effects and Interactions
- Overall: Well tolerated in trials. No severe adverse events over 12 months in the TA-65 meta-analysis.
- Most common: Mild stomach upset — about 12.4% of people reported gastrointestinal symptoms (nausea 7.1%, abdominal discomfort 5.3%).
- Drug interactions: Cycloastragenol inhibits the liver enzymes CYP3A4, CYP2E1, and CYP2C19 in lab studies, which could raise or lower levels of drugs processed by these enzymes — including many statins, blood-pressure medications, and blood thinners.
- Immune effects: Astragalus stimulates the immune system, which is a reason to be cautious if you have an autoimmune condition or take immunosuppressants.
- Cancer concern: Telomerase activation is a double-edged sword — it could theoretically support the growth of existing cancers. No long-term study has examined this risk, and the meta-analysis flagged it as unaddressed.
- Pregnancy and breastfeeding: Insufficient safety data — not recommended without medical supervision.
❓ Common Questions About Astragalus
What is astragalus and how does it work?
Astragalus is the root of a plant used in traditional Chinese medicine for over 2,000 years. Its key compounds — astragaloside IV, cycloastragenol, and polysaccharides — are thought to activate telomerase (the enzyme that rebuilds the protective caps on your DNA), reduce inflammation, and switch on your cells’ antioxidant defenses.
What does the evidence actually show?
The strongest human evidence is a 2025 analysis of 8 randomized trials showing the astragalus extract TA-65 lengthened telomeres, especially in people over 60. But that lengthening did not improve strength, frailty, or inflammation. Other trials show modest benefits for heart-failure symptoms and knee function. Overall this is Silver-tier evidence: promising markers, but no proof of longer or better life in people.
What’s the right dose?
The TA-65 trials used 10–50 mg per day. Whole astragalus root extracts are typically taken at 500 mg to 3 grams per day, often standardized to astragalosides or polysaccharides. There is no established “anti-aging” dose, and the high doses used in animal studies don’t translate cleanly to humans.
What are the risks and side effects?
The most common side effect is mild stomach upset — about 12% of people in the TA-65 trials reported nausea or abdominal discomfort. More importantly, the compound cycloastragenol inhibits several liver enzymes, so it can change the levels of other medications. There are no long-term safety studies, and the effect on cancer risk over years is unknown.
Who should avoid it?
People with autoimmune conditions, anyone on medications processed by the CYP3A4 liver enzyme (including many statins, blood-pressure drugs, and blood thinners), and anyone pregnant or breastfeeding should avoid astragalus unless a doctor approves. Because telomerase activation could theoretically help existing cancers grow, anyone with a history of cancer should be cautious.
The Bottom Line
Astragalus is a genuinely interesting supplement because it sits at the center of one of longevity science’s most seductive ideas — that you can lengthen your telomeres and slow cellular aging. The telomere effect is real and measurable in humans, and the heart-failure data is solid enough to take seriously. But the honest read of the 2025 meta-analysis is uncomfortable: longer telomeres did not make people measurably stronger, less frail, or less inflamed.
Our verdict: worth watching, and defensible for specific uses — heart-failure support (under medical care) and possibly joint support — but not yet justified as a general “anti-aging” supplement. The premium TA-65 products are expensive and the company-funded trials show bigger effects than independent ones, which is exactly the pattern we flag as a red flag. If you take it, the concern isn’t usually the herb itself; it’s the drug interactions (CYP3A4) and the untested long-term cancer question.
Medical Disclaimer: This page is for educational purposes only and is not medical advice. Supplements can interact with medications and are not right for everyone. Always consult a qualified healthcare provider before starting any supplement, especially if you are pregnant, breastfeeding, taking medication, or managing a health condition. See our full disclaimer.
Sources
- Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis. Cell Biol Toxicol. 2025. PMID 41286474
- The clinical efficacy of Astragalus-containing Chinese patent medicines in the effective treatment of heart failure: a systematic review and network meta-analysis. Medicine. 2026. PMID 42216323
- Effect and safety of Neiguan acupoint injection with astragalus injection for chronic heart failure: a randomized controlled trial. Front Med. 2026. PMID 42292177
- Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2026. PMID 42277690
- Evaluation of the effect of Astragalus membranaceus saponins on functional performance and knee joint mobility. Nutrients. 2026. PMID 42356230
- Integrated identification and validation of HSP90AA1 as a therapeutic target of Astragalus membranaceus in Alzheimer’s disease. Neuroscience. 2026. PMID 42492887
- In vitro investigation of the effect of cycloastragenol (CAG) on the cytochrome P450 enzyme activities. Arch Biochem Biophys. 2026. PMID 42107731
- Cycloastragenol attenuates osteoarthritis by restoring chondrocyte senescence via the NRF2/NF-κB signaling axis. Sci Rep. 2026. PMID 41813816
- Astragaloside IV attenuates atherosclerosis by regulating endothelial mitophagy via the Nrf2/PINK1/Parkin pathway. Eur J Pharmacol. 2026. PMID 42468675
- Cycloastragenol in inflammation-related diseases: mechanisms, pharmacokinetics, and translational prospects. Front Pharmacol. 2025. PMID 41601951
- Astragalus membranaceus Extract as a Botanical Ingredient for Pigmentary and Anti-Aging Skincare: A Systematic Review. J Drugs Dermatol. 2026. PMID 41493245
- Molecular Mechanisms Underlying the Anti-Diabetic Effects of Astragaloside IV: A Focus on Signaling Pathways. Drug Des Devel Ther. 2026. PMID 42359338